Want to see MDT full AI Analyst Report?
MDT Stock Chart & Stats
$92.02
$1.71(2.06%)
At close: 4:00 PM EDT
$92.02
$1.71(2.06%)
Day’s Range― - ―
52-Week Range$73.31 - $106.33
Previous CloseN/A
Volume1.79M
Average Volume (3M)7.15M
Market Cap
$119.98B
Enterprise Value$129.69K
Total Cash (Recent Filing)$1.79B
Total Debt (Recent Filing)$28.15B
Price to Earnings (P/E)22.9
Beta0.34
Next Earnings
Nov 24, 2026EPS Estimate
1.33Next Dividend Ex-DateN/A
Dividend Yield3.04%
Share Statistics
EPS (TTM)4.09
Shares Outstanding1,279,138,000
10 Day Avg. Volume8,350,534
30 Day Avg. Volume7,150,933
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)2.16
Price to Sales (P/S)2.94
P/FCF Ratio19.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$103.41Price Target Upside12.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)5.98
Revenue Forecast (FY)$39.06B
Bulls Say, Bears Say
Bulls Say
Diversified, Broad-based GrowthGrowth across operating units, geographies and procedure volumes reduces dependence on any single therapy or market. This breadth supports more durable revenue expansion, improves resilience through product cycles, and gives Medtronic multiple avenues to sustain momentum over the next several quarters.
Strong Margins And Cash GenerationHigh gross and operating margins indicate meaningful economics across Medtronic’s device portfolio, while growing free cash flow supports research, acquisitions, dividends and debt management. This combination strengthens financial flexibility and helps fund durable competitive investment without relying solely on external capital.
Innovation And Share GainsExceptional growth in cardiac ablation and share gains in rhythm management show that Medtronic is converting innovation into adoption and competitive progress. A larger installed base, expanding clinical platforms and new indications can reinforce recurring procedure-related revenue over time.
Bears Say
Elevated Debt And Rising LeverageAlthough equity supports a moderate leverage profile, elevated absolute debt and a higher leverage trajectory can reduce financial flexibility if growth slows or capital costs rise. More cash may be required for interest, refinancing or balance-sheet repair, constraining future capital allocation.
Neuromodulation Market SoftnessWeakness in spinal cord stimulation and replacement demand weighs on an established neuroscience franchise and can limit segment growth while newer products scale. Continued softness may require additional innovation, evidence generation or commercial investment to restore durable momentum.
Unfavorable Business Mix PressureRapid growth in Diabetes and Cardiac Ablation Solutions is currently associated with an unfavorable capital mix that pressures gross margin. If these businesses continue to represent a larger share of revenue, mix effects could temper margin expansion even as operating performance improves.
Medtronic News
MDT FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was $73.31 and its highest was $106.33 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is $119.98B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Nov 24, 2026 which is in 69 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Sep 01, 2026. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.388 by $0.062.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 3.04%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.33.
How many shares outstanding does Medtronic have?
Medtronic has 1,279,138,000 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.45 in its last earnings report, beating expectations of $1.388. Following the earnings report the stock price went up 1.533%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in MDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$103.41 (12.38% Upside)
$103.41 (12.38% Upside)
Blogger Sentiment
Bullish
MDT Sentiment 78%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.60%
12-Months-Change
Fundamentals
Return on Equity
3.04%
Trailing 12-Months
Asset Growth
2.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medtronic
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
MDT Company Deck
MDT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Medtronic reported broad-based revenue and earnings outperformance, significant growth in Cardiac Ablation Solutions, continued momentum in CRM, CST, Surgical, Pelvic Health and Diabetes, improved operating metrics, stronger cash conversion and raised fiscal 2027 guidance. The principal challenges were business-mix pressure on gross margin, neuromodulation softness, low-single-digit Structural Heart growth, expected moderation in some growth rates, and foreign exchange and tariff headwinds.View all MDT earnings summariesMDT Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
MDT Stock 12 Month Forecast
Average Price Target
$103.41
▲(12.38% Upside)
Technical Analysis
Ownership Overview
0.08% Insiders
25.55% Mutual Funds
16.60% Other Institutional Investors
32.68% Public Companies and Individual Investors